Cresco Labs (CRLBF) Income from Continuing Operations (2020 - 2026)
Cresco Labs (CRLBF) posted Income from Continuing Operations of 11426000.0 for Q1 2026, up 113.39% on a QoQ basis from 85341000.0 in Q4 2025, and down 14.72% year-over-year from 13398000.0 in Q1 2025.
Cresco Labs (CRLBF) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cresco Labs' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 11426000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 14.72% year-over-year to 11426000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 52770000.0 (down 382.13% YoY) and the FY2025 annual result came in at 140044000.0, down 131.52% from the prior year.
- Income from Continuing Operations was 11426000.0 for Q1 2026 at Cresco Labs, up from 85341000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 38980000.0 in Q2 2022 and bottomed at 133101000.0 in Q4 2022.
- A 5-year average of 8943176.47 and a median of 11426000.0 in 2026 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 484.76% — and 2025, when it sank 1604.87%.
- Cresco Labs' Income from Continuing Operations stood at 133101000.0 in 2022, then jumped by 115.6% to 20768000.0 in 2023, then plunged by 72.69% to 5671000.0 in 2024, then sank by 1604.87% to 85341000.0 in 2025, then soared by 113.39% to 11426000.0 in 2026.
- Business Quant data shows CRLBF's Income from Continuing Operations at 11426000.0 in Q1 2026, 85341000.0 in Q4 2025, and 1766000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 11.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.43 Mn |
| Dec 31, 2025 | -85.34 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 19.38 Mn |
| Mar 31, 2025 | 13.40 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Sep 30, 2024 | 30.34 Mn |
| Jun 30, 2024 | -30.70 Mn |
| Mar 31, 2024 | 33.95 Mn |
| Dec 31, 2023 | 20.77 Mn |
| Sep 30, 2023 | -124.94 Mn |
| Jun 30, 2023 | -15.59 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Dec 31, 2022 | -133.10 Mn |
| Sep 30, 2022 | 34.22 Mn |
| Jun 30, 2022 | 38.98 Mn |
| Mar 31, 2022 | 21.94 Mn |
| Dec 31, 2021 | 35.15 Mn |
| Sep 30, 2021 | -219.60 Mn |
| Jun 30, 2021 | 29.58 Mn |